Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Chemotherapy, host response and molecular dynamics in periampullary cancer : The CHAMP study

Hau, Sofie Olsson LU ; Petersson, Alexandra LU ; Nodin, Björn LU ; Karnevi, Emelie LU ; Boman, Karolina LU ; Williamsson, Caroline LU ; Eberhard, Jakob LU ; Leandersson, Karin LU orcid ; Gisselsson, David LU and Heby, Margareta LU , et al. (2020) In BMC Cancer 20(1).
Abstract

Background: Pancreatic cancer is a devastating disease with a dismal prognosis. Despite profound medical advances in systemic therapies for other types of aggressive tumours during recent years, a diagnosis of pancreatic cancer is still often synonymous with a fatal outcome. The term periampullary cancer includes pancreatic cancer and applies to the group of tumours found in proximity to the ampulla of Vater. Molecular events and immune response in the host during chemotherapy remain largely unexplored in this group of tumours. Therefore, the "Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer (CHAMP)" study aims to monitor these processes to gain new insight into this perplexing disease. Methods: The CHAMP study... (More)

Background: Pancreatic cancer is a devastating disease with a dismal prognosis. Despite profound medical advances in systemic therapies for other types of aggressive tumours during recent years, a diagnosis of pancreatic cancer is still often synonymous with a fatal outcome. The term periampullary cancer includes pancreatic cancer and applies to the group of tumours found in proximity to the ampulla of Vater. Molecular events and immune response in the host during chemotherapy remain largely unexplored in this group of tumours. Therefore, the "Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer (CHAMP)" study aims to monitor these processes to gain new insight into this perplexing disease. Methods: The CHAMP study is a prospective, single-arm observational study. All patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant or palliative chemotherapy treatment in the Department of Oncology, Skåne University Hospital, are invited to participate. Clinical and pathological data will be compiled at study entry. A single tissue microarray (TMA) block is constructed for each patient with a resected tumour and blood samples are drawn before, during and after chemotherapy in order to sample peripheral blood mononuclear cells (PBMC), cytokines and circulating tumour DNA (ctDNA). Next generation sequencing will be performed on tumour tissue and ctDNA to detect changes in the clonal landscape over space and time. Discussion: Despite the recent emergence of some promising biomarkers for periampullary cancer, there has been a lack of success in clinical implementation. Cancer cells continuously adapt and become resistant to treatment during chemotherapy. To be able to keep pace with and hopefully overtake this rapid evolution we must, with the help of new diagnostic tools, be ready to adapt and alter treatment accordingly. It seems to us that the only way forward is to gain a better understanding of the dynamics of the disease during treatment. With insights gained from the CHAMP study we hope to find answers to key questions in this largely unexplored territory. Trial registration: This study has been registered 30th October 2018 at clinicaltrials.gov as NCT03724994.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Chemotherapy, ctDNA, Immune response, Pancreatic cancer, Periampullary cancer
in
BMC Cancer
volume
20
issue
1
article number
308
publisher
BioMed Central (BMC)
external identifiers
  • pmid:32293352
  • scopus:85083416411
ISSN
1471-2407
DOI
10.1186/s12885-020-06807-3
project
Chemotherapy, Host response And Molecular dynamics in Periampullary cancer
Genetic Topography and Tumor Immunogenecity of Pancreatic Cancer
Disease and illness trajectories of pancreatic cancer
language
English
LU publication?
yes
id
aa990311-63da-4983-ae69-3eeb6fecfe8c
date added to LUP
2020-04-30 08:27:18
date last changed
2024-03-04 18:14:28
@article{aa990311-63da-4983-ae69-3eeb6fecfe8c,
  abstract     = {{<p>Background: Pancreatic cancer is a devastating disease with a dismal prognosis. Despite profound medical advances in systemic therapies for other types of aggressive tumours during recent years, a diagnosis of pancreatic cancer is still often synonymous with a fatal outcome. The term periampullary cancer includes pancreatic cancer and applies to the group of tumours found in proximity to the ampulla of Vater. Molecular events and immune response in the host during chemotherapy remain largely unexplored in this group of tumours. Therefore, the "Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer (CHAMP)" study aims to monitor these processes to gain new insight into this perplexing disease. Methods: The CHAMP study is a prospective, single-arm observational study. All patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant or palliative chemotherapy treatment in the Department of Oncology, Skåne University Hospital, are invited to participate. Clinical and pathological data will be compiled at study entry. A single tissue microarray (TMA) block is constructed for each patient with a resected tumour and blood samples are drawn before, during and after chemotherapy in order to sample peripheral blood mononuclear cells (PBMC), cytokines and circulating tumour DNA (ctDNA). Next generation sequencing will be performed on tumour tissue and ctDNA to detect changes in the clonal landscape over space and time. Discussion: Despite the recent emergence of some promising biomarkers for periampullary cancer, there has been a lack of success in clinical implementation. Cancer cells continuously adapt and become resistant to treatment during chemotherapy. To be able to keep pace with and hopefully overtake this rapid evolution we must, with the help of new diagnostic tools, be ready to adapt and alter treatment accordingly. It seems to us that the only way forward is to gain a better understanding of the dynamics of the disease during treatment. With insights gained from the CHAMP study we hope to find answers to key questions in this largely unexplored territory. Trial registration: This study has been registered 30th October 2018 at clinicaltrials.gov as NCT03724994.</p>}},
  author       = {{Hau, Sofie Olsson and Petersson, Alexandra and Nodin, Björn and Karnevi, Emelie and Boman, Karolina and Williamsson, Caroline and Eberhard, Jakob and Leandersson, Karin and Gisselsson, David and Heby, Margareta and Jirström, Karin}},
  issn         = {{1471-2407}},
  keywords     = {{Chemotherapy; ctDNA; Immune response; Pancreatic cancer; Periampullary cancer}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{BMC Cancer}},
  title        = {{Chemotherapy, host response and molecular dynamics in periampullary cancer : The CHAMP study}},
  url          = {{http://dx.doi.org/10.1186/s12885-020-06807-3}},
  doi          = {{10.1186/s12885-020-06807-3}},
  volume       = {{20}},
  year         = {{2020}},
}